Urteste Expands Its Diagnostic Portfolio with Innovative Projects
Urteste S.A. (Warsaw Stock Exchange: URT) is making significant strides in the field of cancer diagnostics. The biotechnology firm specializes in breakthrough technology designed to detect cancer from urine samples. Its flagship project, PANURI, focuses on diagnosing pancreatic cancer effectively and efficiently. The innovative approach utilizes proprietary synthetic peptides to analyze enzyme activity in urine, allowing for the detection of multiple cancer types with a single sample.
Revolutionizing Cancer Detection
The promising technology developed by Urteste is characterized by its non-invasive nature and cost-effectiveness. It has demonstrated high sensitivity and specificity, producing results within two hours. A proof-of-concept study involving 322 participants highlighted the PANURI test's impressive sensitivity of 95.6% and specificity of 95.5%. This precision positions Urteste at the forefront of non-invasive cancer diagnostics, leveraging automation to mitigate human error during testing.
Upcoming Clinical Trials in the US
Currently, Urteste is actively involved in the FDA Q-Submission program. The company is in search of a qualified Contract Research Organization (CRO) to assist in conducting clinical trials within the United States. These trials are a critical step toward validation and regulatory approval, enhancing Urteste's ability to commercialize their groundbreaking PANURI test.
New Breast Cancer Project: NASTRO
In addition to PANURI, Urteste is excited to announce the development of a new diagnostic test for breast cancer named NASTRO. The project recently received a non-refundable grant of approximately $3 million from the Polish Agency for Enterprise Development. This funding will play a crucial role in advancing clinical trials, moving NASTRO closer to market readiness.
Significance of Early Detection
Breast cancer remains a significant health concern globally. The "Global Cancer Statistics 2022" report indicates there were over 2.3 million new cases and nearly 700,000 deaths due to breast cancer in that year alone. Grzegorz Stefa?ski, CEO, expressed optimism for the NASTRO project, emphasizing the vital need for a non-invasive diagnostic method that accurately identifies breast cancer at its nascent stages. He highlighted Urteste's commitment to progress while maintaining a strong focus on the PANURI project.
A Comprehensive Portfolio for Cancer Diagnostics
Urteste operates the MULTI-CANCER initiative, which encompasses a robust pipeline of 12 prototype diagnostic tests targeting various cancers. This portfolio includes tests for pancreatic, brain, breast, stomach, bile duct, ovarian, endometrial, kidney, colorectal, lung, liver, and prostate cancers — collectively addressing nearly 70% of cancer-related fatalities worldwide.
Global Patent Strategy
The company's technology is protected by Polish patents and international patent applications, indicating a strategic focus on regions that account for around 90% of the world’s GDP. This approach not only secures Urteste's innovations but also broadens their market potential and operational capacity in cancer diagnostics.
Upcoming Participation at MEDICA
As part of its outreach and networking efforts, Urteste plans to attend MEDICA, a prominent medical trade fair in Düsseldorf, Germany, scheduled for November. This event will provide an invaluable opportunity for Urteste to showcase their innovations and connect with professionals in the healthcare industry.
Conclusion: Commitment to Early Cancer Detection
Urteste is dedicated to revolutionizing the field of cancer diagnostics through pioneering technologies and a strong commitment to research and development. With their motto "Early cancer detection saves lives," the company is focused on enhancing its diagnostic capabilities, which is crucial in the fight against cancer. Their efforts combine scientific expertise with clinical application, ultimately aiming to save lives through timely and accurate diagnosis.
Frequently Asked Questions
What is Urteste S.A. known for?
Urteste S.A. specializes in developing innovative diagnostic tests for various cancers, utilizing urine samples to detect cancer early.
What is the PANURI project?
PANURI is Urteste's flagship project aimed at developing a diagnostic test for pancreatic cancer, boasting high sensitivity and specificity.
What stage is the NASTRO project currently in?
The NASTRO project is in the development phase, recently funded by a $3 million grant to support its clinical trials.
How does Urteste ensure accuracy in its tests?
Urteste employs proprietary synthetic peptides to measure enzyme activity in urine, allowing for precise cancer detection.
Where will Urteste showcase its innovations?
Urteste will participate in MEDICA in Düsseldorf, Germany, presenting its cutting-edge diagnostic technologies to industry professionals.
